Evoke Pharma’s Gimoti NDA targets female gastroparesis patients with novel delivery approach

Evoke Pharma’s (NASDAQ:EVOK) discovery that its metoclopramide nasal spray, known as Gimoti, to treat symptoms of gastroparesis, a delayed emptying of stomach contents, reduced symptoms in women, but not in men, and that metoclopramide has significantly different exposure in men, compared with women, led the company to file a female-only NDA with the FDA in June.

Read More
FeatureLeonard Zehr
ASLAN Pharma gears up for data rich second half

ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the treatment of biliary tract (BTC) and gastric cancers, and with ASLAN003 for the treatment of acute myeloid leukemia (AML).

Read More
FeatureLeonard Zehr